SS
ATRA icon

Steve Schonfeld’s Atara Biotherapeutics ATRA Stock Holding History

Steve Schonfeld’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,880
Closed -$102K – 2141
2024
Q1 		$102K Buy
+5,880
New +$104K ﹤0.01% 1848
2022
Q4 		– Sell
-1,154
Closed -$109K – 2577
2022
Q3 		$109K Buy
+1,154
New +$130K ﹤0.01% 2523
2017
Q3 		– Sell
-786
Closed -$275K – 589
2017
Q2 		$275K Buy
+786
New +$303K 0.03% 501

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Steve Schonfeld's ATRA Position: Q2 2024 in Review

Steve Schonfeld sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 5,880 shares — an estimated $102K sold.

Steve Schonfeld first reported a position in ATRA in Q2 2017 and held it in 3 quarters. The position peaked at $275K in Q2 2017. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Steve Schonfeld reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Steve Schonfeld sold 5,880 Atara Biotherapeutics shares in Q2 2024, an estimated $102K.
  • Steve Schonfeld first reported a position in Atara Biotherapeutics in Q2 2017 and held it in 3 quarters.
  • Steve Schonfeld's Atara Biotherapeutics position peaked at $275K in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.